Analysts Set Fluidigm Co. (NASDAQ:FLDM) Target Price at $12.67

Share on StockTwits

Fluidigm Co. (NASDAQ:FLDM) has been assigned a consensus recommendation of “Hold” from the seven brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $12.67.

Several analysts recently issued reports on the stock. UBS Group raised shares of Fluidigm from a “neutral” rating to a “buy” rating and cut their price target for the company from $14.00 to $7.00 in a report on Friday, October 18th. Janney Montgomery Scott cut shares of Fluidigm from a “buy” rating to a “neutral” rating in a report on Wednesday, November 6th. Zacks Investment Research cut shares of Fluidigm from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, BidaskClub raised shares of Fluidigm from a “sell” rating to a “hold” rating in a report on Saturday, November 2nd.

Shares of FLDM stock opened at $2.30 on Monday. The company has a market capitalization of $174.61 million, a PE ratio of -2.88 and a beta of 2.30. The firm has a fifty day simple moving average of $4.01 and a 200-day simple moving average of $8.22. The company has a current ratio of 2.89, a quick ratio of 2.44 and a debt-to-equity ratio of 0.33. Fluidigm has a twelve month low of $2.12 and a twelve month high of $14.90.

Fluidigm (NASDAQ:FLDM) last announced its earnings results on Tuesday, November 5th. The medical research company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.01. The business had revenue of $26.50 million during the quarter, compared to the consensus estimate of $28.74 million. Fluidigm had a negative net margin of 57.10% and a negative return on equity of 25.11%. The business’s quarterly revenue was down 8.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.13) earnings per share. Equities research analysts predict that Fluidigm will post -0.6 EPS for the current year.

In other Fluidigm news, insider Levin Easterly Partners Llc sold 11,545 shares of the stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $5.55, for a total transaction of $64,074.75. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.00% of the stock is currently owned by corporate insiders.

Several large investors have recently modified their holdings of the business. Metropolitan Life Insurance Co NY bought a new position in shares of Fluidigm during the first quarter worth about $151,000. FMR LLC bought a new position in shares of Fluidigm during the first quarter worth about $24,188,000. First Quadrant L P CA grew its position in shares of Fluidigm by 25.1% during the second quarter. First Quadrant L P CA now owns 32,675 shares of the medical research company’s stock worth $403,000 after acquiring an additional 6,563 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Fluidigm during the second quarter worth about $5,360,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Fluidigm during the second quarter worth about $68,000. 97.13% of the stock is currently owned by institutional investors.

Fluidigm Company Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.

Featured Article: Holder of Record

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Mayne Pharma Group  Shares Cross Below 200 Day Moving Average of $0.54
Mayne Pharma Group Shares Cross Below 200 Day Moving Average of $0.54
Reject Shop  Share Price Crosses Below Two Hundred Day Moving Average of $2.15
Reject Shop Share Price Crosses Below Two Hundred Day Moving Average of $2.15
NWF Group  Stock Price Passes Below 200 Day Moving Average of $165.06
NWF Group Stock Price Passes Below 200 Day Moving Average of $165.06
Berkeley Energia  Shares Pass Below 200 Day Moving Average of $15.59
Berkeley Energia Shares Pass Below 200 Day Moving Average of $15.59
Fresnillo Plc  Receives $9.00 Average Price Target from Brokerages
Fresnillo Plc Receives $9.00 Average Price Target from Brokerages
Royal Bank of Canada  Price Target Lowered to $102.00 at Credit Suisse Group
Royal Bank of Canada Price Target Lowered to $102.00 at Credit Suisse Group


© 2006-2019 Ticker Report